VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
134 hedge funds and large institutions have $260M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 40 reducing their positions, and 12 closing their positions.
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
18% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 40
6% more funds holding
Funds holding: 126 → 134 (+8)
0% less call options, than puts
Call options by funds: $1.89M | Put options by funds: $1.9M
25% less capital invested
Capital invested by funds: $347M → $260M (-$87.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.3M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.59M |
| 3 |
Millennium Management
New York
|
+$1.51M |
| 4 |
BlackRock
New York
|
+$1.3M |
| 5 |
Rafferty Asset Management
New York
|
+$956K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.72M |
| 3 |
HF
HRT Financial
New York
|
-$929K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$894K |
| 5 |
E
Ergoteles
New York
|
-$532K |
VBIV Hedge Fund Activity: Q4 2021 in Review
134 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q4 2021, worth a combined $260M — down 25% from $347M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VBIV positions and 12 closed out — a net gain of 8 holders — while 47 added to existing stakes and 40 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $2.3M. The largest seller was Perceptive Advisors, cutting an estimated $7.6M.
- 134 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q4 2021, up from 126 in Q3 2021.
- Funds reported $260M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q4 2021, down 25% quarter-over-quarter.
- 20 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q4 2021 and 12 closed out, a net change of +8 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q4 2021 was Goldman Sachs, an estimated $2.3M added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q4 2021 was Perceptive Advisors, an estimated $7.6M sold.
Based on aggregated 13F filings for Q4 2021.